This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN), Bayer (ETR: BAYN), and Merck have committed to funding the whole-genome sequencing (WGS) of 250,000 individuals. This significant commitment is in support of the Alliance for Genomic Discovery (AGD), a partnership led by Illumina (NASDAQ: ILMN) and Nashville Biosciences. The initiative aims to accelerate drug development through genomics and multiomics-based methods.
Alliance for Genomic Discovery Aims to Boost Drug Development
The AGD’s mission is to harness the power of genomics to transform drug development. By sequencing the genomes of 250,000 individuals, the alliance will generate a vast database that can be used to identify new targets for therapeutic intervention, understand disease mechanisms, and develop personalized treatment strategies.
Collaboration in Genomics to Drive Innovation
This collaboration represents a significant commitment from the pharmaceutical industry to invest in genomic research. It underscores the recognition of the importance of genomic data in driving innovation in drug discovery and development. The support from these major players will provide the AGD with the resources needed to advance genomic research and apply findings to improve patient outcomes.-Fineline Info & Tech
